The study conducted by Johns Hopkins in a two-part study to explore and locate current drugs on the market for other deceases and conditions could treat prostate cancer. The researchers screened 38 non-chemotherapy drugs to see if they had any effect on cancer. The research found out that Digoxin reduced the growth of prostate cancer cells in the laboratory by 50%
Identification of novel indications for commonly prescribed drugs could accelerate translation of therapies. We investigated whether any clinically used drugs might be useful in treating prostate cancer by coupling an efficient, high-throughput laboratory-based screen and a large prospective cohort study. In stage one, we conducted an in vitro prostate cancer cell cytotoxicity screen of 3,187 compounds. Digoxin emerged as the leading candidate, given its potency in inhibiting proliferation in vitro (the concentration of the drug at which proliferation was inhibited by 50%: mean of 163 nM) and its common use. In stage two, we evaluated the association between the leading candidate drug from stage one and prostate cancer risk in 47,884 men followed up from 1986 through 2006. Regular digoxin users [vs nonusers: relative risk (RR) = 0.76; 95% confidence interval (CI), 0.61–0.95], especially users for ≥10 years (RR = 0.54; 95% CI, 0.37–0.79; P trend < 0.001), had a lower prostate cancer risk. Digoxin was highly potent in inhibiting prostate cancer cell growth in vitro, and its use was associated with a 25% lower prostate cancer risk.
The second part of the study, conducted from 1986 - 2006, they examined the impact of digoxin use in 47,884 men between the ages of 40 and 75 who participated. fter 20 years, some 5,000 cases of prostate cancer had been reported. The digoxin users had a 25% lower risk of prostate cancer than nonusers, and the risk was lower still among men who had used the drug for 10 years or longer.
You can read the complete article over at the Journal Cancer Discovery Research paper.